Carcinogenicity testing and the evaluation of regulatory requirements for pharmaceuticals

Regulatory Toxicology and Pharmacology

Volumn 25, Issue 2, 1997, Pages 130-145

  Contrera, Joseph F ^a   Jacobs, Abigail C ^a   DeGeorge, Joseph J ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTIDIABETIC AGENT; ANTIEMETIC AGENT; ANTIFUNGAL AGENT; ANTIHISTAMINIC AGENT; ANTIHYPERTENSIVE AGENT; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; ANXIOLYTIC AGENT; BRONCHODILATING AGENT; CENTRAL STIMULANT AGENT; CONTRACEPTIVE AGENT; CORONARY VASODILATING AGENT; CORTICOSTEROID; DIURETIC AGENT; HYPNOTIC AGENT; IMMUNOSUPPRESSIVE AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; RETINOID; SEDATIVE AGENT;

ANIMAL MODEL; ARTICLE; CARCINOGEN TESTING; CONTROLLED STUDY; DATA BASE; FEMALE; INTERMETHOD COMPARISON; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; QUALITY CONTROL; RAT; RISK ASSESSMENT; SPECIES DIFFERENCE;

EID: 0031128199     PISSN: 02732300     EISSN: None     Source Type: Journal    
DOI: 10.1006/rtph.1997.1085     Document Type: Article

References (35)

1. Adams J. M., Cory S. Transgenic models of tumor development. Science. 254:1991;1161-1167.
2. Ashby J., Tennant R. W. Definitive relationships among chemical structure, carcinogenicity and mutagenicity for 301 chemicals by the U.S. NTP. Mutation Res. 257:1991;229-306.
3. Boyle C. C. An overview of the Keystone Symposium on molecular toxicology, Copper Mountain, CO, 9-15 January 1995. Human Exper. Toxicol. 14:1995;393-398.
4. Bremner R., Balmain A. Genetic changes in skin tumor progression: Correlation between presence of a mutant ras gene and loss of heterozygosity on mouse chromosome 7. Cell. 61:1990;407-417.
5. Cleaver J. E., Kraemer K. H. Pigmentosum and Cockayne syndrome. The Metabolic Basis of Inherited Disease. 1994;McGraw-Hill, New York. p. 4393-4419.
6. Della Porta G., Dragani T. A. Teratog. Carcinog. Mutagen. 10:1990;137-145.
7. De Vries A., van Oostrom C. T. M., Hofhuis F. M. A., Dortant P. M., Berg R. J. W., de Gruijl F. R., Wester P. W., van Kreijl C. F., Capel P. J. A., van Steeg H., Verbeek S. J. Increased susceptibility to ultraviolet-B and carcinogens of mice lacking the DNA excision repair gene XPA. Nature. 377:1995;169-173.
8. Fearon E. R., Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 61:1990;759-767.
9. Freedman D. A., Gold L. S., Lin T. H. Concordance between rats and mice in bioassays for carcinogenesis. Regul. Toxicol. Pharmacol. 23:1996;225-232.
10. Fujii K. Evaluation of the newborn mouse model for chemical tumorigenesis. Carcinogenesis. 12:1991;1409-1415.
11. Gold L. S., Bernstein L., Magaw R., Slone T. H. Interspecies extrapolation in carcinogenesis: prediction between rats and mice. Environ. Health Perspect. 81:1989;211-219.
12. Gold L. S., Manley N., Slone T., Garfinkel G., Rohrback L., Ames B. N. The fifth plot of the carcinogenic potency database: Results of animal bioassays published in the general literature through 1988, by the National Toxicology Program through 1989. Environ. Health Perspect. 100:1993a;65-135.
13. Gold L. S., Slone T. H., Manley N. B., Bernstein L. Target organs in chronic bioassays of 533 chemical carcinogens. Environ. Health Perspect. 93:1991;233-246.
14. Gold L. S., Slone T. H. Prediction of carcinogenicity from 2 vs. 4 sex-species groups in the carcinogenic potency database. J. Toxicol. Environ. Health. 39:1993b;147-161.
15. Goldsworthy T. L., Recio L., Brown K., Donehower L. A., Mirsalis J. C., Tennant R. W., Purchase I. F. H. Symposium overview: Transgenic animals in toxicology. Fundam. Appl. Toxicol. 22:1994;8-19.
16. Gray G. M., Li P., Shlyakhter I., Wilson R. An empirical examination of factors influencing prediction of carcinogenic hazard across species. Reg. Toxicol. Pharm. 22:1995;283-291.
17. Haseman J. K., Lockhart A. Correlations between chemically related site-specific carcinogenic effects in long-term studies in rats and mice. Environ. Health Perspect. 101:1993;50-54.
18. Haseman J. K., Winbush J. S., O'Donnell M. W. Jr. Use of dual control groups to estimate false positive rates in laboratory animal carcinogenicity studies. Fundam. Appl. Toxicol. 7:1986;573-584.
19. Haseman J. K. A re-examination of false-positive rates for carcinogenicity studies. Fundam. Appl. Toxicol. 3:1983;334-339.
20. Hollstein M., Sidransky D., Vogelstein B., Harris C. C. p53 mutations in human cancers. Science. 253:1991;49-53.
21. Huff J., Cirvello J., Haseman J., Bucher J. Chemicals associated with site-specific neoplasia in 1394 long-term carcinogenesis experiments in laboratory rodents. Environ. Health Perspect. 93:1991b;247-270.
22. Huff J., Haseman J. Long-term chemical carcinogenesis experiments for identifying potential human cancer hazards: Collective database of the National Cancer Institute and National Toxicology Program. Environ. Health Perspect. 96:1991a;23-31.
23. Huff J., Haseman J., Rall D. Scientific concepts, value, and significance of chemical carcinogenesis studies. Annu. Rev. Pharmacol. Toxicol. 31:1991c;621-652.
24. McConnell E. E., Solleveld H. A., Swenberg J. A., Boorman G. A. Guidelines for combining neoplasms for evaluation of rodent carcinogenesis studies. J. Natl. Cancer Inst. 76:1986;283-394.
25. Nakasato F., Sakamoto H., Mori M., Hayashi K., Shimosato Y., Nishi M., Takao S., Nakatani K., Terada M., Sugimura T. Amplification of the c-myc oncogene in human stomach cancers. Jpn. J. Cancer Res. 75:1984;737-742.
26. National Toxicology Program, Board of Scientific Counselors, 1984, Report of the NTP Ad Hoc Panel on Chemical Carcinogenesis Testing and Evaluation.
27. OSTP, Exec. Off. President Fed. Regist. 50:1985;10371-10442.
28. Piegorsch W. W., Carr G. J., Hoel D. G. Concordance of carcinogenic response between rodent species: Potency dependence and potential underestimation. Risk Anal. 12:1992;115-121.
29. Pietra G., Rappaport H., Shubik P. The effects of carcinogenic chemicals in newborn mice. Cancer. 14:1961;308-317.
30. Saitoh A. Most tumors in transgenic mice with human c-Ha-ras gene contain somatically activated transgenes. Oncogene. 5:1990;1195-1200.
31. Sullivan N., Gatehouse D., Tweats D. Mutation, cancer and transgenic models: Relevance to the toxicology industry. Mutagenesis. 8:1993;167-174.
32. Tennant R. W. Stratification of rodent carcinogenicity bioassay results to reflect relative human hazard. Mutat. Res. 286:1993;111-118.
33. Tennant R. W., French J. E., Spalding J. W. Identifying chemical carcinogens and assessing potential risk in short-term bioassays using transgenic mouse models. Environ. Health Perspect. 103:1995;942-950.
34. Tennant R. W., Spalding J., French J. E. Evaluation of transgenic mouse bioassays for identifying carcinogens and non carcinogens. Mutat. Res. 1996.
35. Vogelstein B. Cancer: A deadly inheritance. Nature. 348:1990;681-682.